B. Riley Lowers PDS Biotechnology (NASDAQ:PDSB) Price Target to $7.00

PDS Biotechnology (NASDAQ:PDSB) had its target price lowered by B. Riley from $9.00 to $7.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. B. Riley’s price target would suggest a potential upside of 231.75% from the company’s previous close.

Other analysts have also issued research reports about the company. StockNews.com lowered PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research report on Friday, November 15th. Finally, Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

PDS Biotechnology Stock Down 2.8 %

Shares of NASDAQ PDSB opened at $2.11 on Monday. The firm has a market cap of $78.94 million, a price-to-earnings ratio of -1.82 and a beta of 1.93. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a 52-week low of $1.53 and a 52-week high of $6.68. The business’s 50 day moving average is $3.08 and its two-hundred day moving average is $3.18.

Institutional Trading of PDS Biotechnology

Large investors have recently modified their holdings of the stock. Tempus Wealth Planning LLC purchased a new stake in shares of PDS Biotechnology during the second quarter worth $55,000. Ground Swell Capital LLC purchased a new stake in shares of PDS Biotechnology during the second quarter worth $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of PDS Biotechnology during the second quarter worth $115,000. Squarepoint Ops LLC purchased a new stake in shares of PDS Biotechnology during the second quarter worth $120,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of PDS Biotechnology during the second quarter worth $146,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.